TNF Pharmaceuticals, Inc.

General Information

Company Name

Founded Year

2014

Location (Offices)

Baltimore, United States +1

Founders / Decision Makers

Number of Employees

Industries

Biotechnology, Pharmaceutical

Funding Stage

Post Ipo Equity

Social Media

TNF Pharmaceuticals, Inc. - Company Profile

MyMD Pharmaceuticals, with the slogan "Novel immunotherapies targeting autoimmune and age-related diseases", is a clinical stage biotech pharmaceutical company aiming to extend healthy lifespan through the development of two therapeutic platforms.

MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control tumor necrosis factor alpha (TNF-α) and other pro-inflammatory cytokines. It is intended for the treatment of autoimmune diseases, including those currently treated with non-selective TNF-α blocking drugs, as well as aging and longevity.

Additionally, MyMD is working on Supera-CBD, a drug platform based on a novel synthetic derivative of cannabidiol (CBD) targeting key receptors including CB2 and opioid receptors. This platform aims to address the ever-growing CBD market, which encompasses FDA approved drugs and non-regulated CBD products.

Founded in 2014 and headquartered in the United States, MyMD has recently secured a $7.00M post-IPO equity investment on 21 May 2024 from PharmaCyte Biotech. The company's focus on innovative solutions for debilitating diseases and aging-related issues makes it an intriguing venture for potential investors.

Taxonomy: Immunotherapy, Autoimmune diseases, Aging, Longevity, Biotech pharmaceuticals, Clinical stage, Small molecule drugs, TNF-α, Pro-inflammatory cytokines, CBD derivatives, CB2 receptors, Opioid receptors, Monoamine oxidase inhibition, FDA approved drugs